Patents Assigned to Children's Hospital, Inc.
-
Patent number: 8597254Abstract: The present invention is a protective sleeve for containing medical lines, comprising: (a) a foldable sleeve comprising first and second side panels, and adapted to be opened and closed along its longitudinal axis so as to form a conduit for medical lines, at least one of the panels being transparent, the foldable sleeve adapted to be reversibly opened along its longitudinal axis, and having releasable closures to maintain the foldable sleeve in a folded closed position; and (b) a plurality of rigid members incorporated into the sleeve and along the longitudinal axis.Type: GrantFiled: September 9, 2010Date of Patent: December 3, 2013Assignee: Nationwide Children's Hospital, Inc.Inventors: Joyce Mullet, Nancy Ryan-Wenger, Micah Skeens
-
Publication number: 20130244935Abstract: Methods of treating, abating and reducing the lisk for necrotizing enterocolitis (NEC) in an infant are disclosed. Preferred methods include admmistering an EGF receptor agonist, such as HB-EGF or EGF, within 24 hours following birth or following the onset of at least one symptom of NEC, in an amount effective to reduce the onset or seventy of NEC.Type: ApplicationFiled: March 11, 2013Publication date: September 19, 2013Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventor: Gail E. Besner
-
Publication number: 20130225666Abstract: The present invention relates to Adeno-associated virus 9 methods and materials useful for systemically delivering polynucleotides across the blood brain barrier. Accordingly, the present invention also relates to methods and materials useful for systemically delivering polynucleotides to the central and peripheral nervous systems. The present invention also relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as spinal muscle atrophy and amyotrophic lateral sclerosis as well as Pompe disease and lysosomal storage disorders. Use of the methods and materials is also indicated, for example, for treatment of Rett syndrome.Type: ApplicationFiled: March 14, 2013Publication date: August 29, 2013Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: BRIAN K. KASPAR, KEVIN FOUST
-
Publication number: 20130216502Abstract: The invention provides for methods of treating, abating and reducing the risk for intestinal injury by administering a combination heparin binding epidermal growth factor (HB-EGF) and stem cells, such as mesenchymal stem cells or intestinal stem cells, in an amount effective to reduce the onset or severity of intestinal injury. The invention also provides for methods of promoting engraftment of stem cells, such as mesenchymal stem cells or intestinal stem cells, within the intestine of a patient suffering from intestinal injury.Type: ApplicationFiled: February 22, 2012Publication date: August 22, 2013Applicant: NATIONWIDE CHILDREN'S HOSPITAL INC.Inventor: Gail E. Besner
-
Patent number: 8486420Abstract: The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an immune response by administration of the same to a subject.Type: GrantFiled: February 15, 2006Date of Patent: July 16, 2013Assignees: The University of North Carolina at Chapel Hill, Children's Hospital, Inc.Inventors: Robert E. Johnston, Philip R. Johnson, Christy K. Jurgens, Kelly Young Poe
-
Publication number: 20130165376Abstract: The invention is related to methods of protecting, preventing and reducing intestinal injury in a human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation (HS/R) comprising administering heparin binding epidermal growth factor (HB-EGF). The invention is also related to methods of inhibiting deterioration of intestinal blood flow and methods of preserving and increasing intestinal blood flow by administering HB-EGF to a human subject. In addition, the methods of the invention should improve the clinical outcome of human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation.Type: ApplicationFiled: January 9, 2012Publication date: June 27, 2013Applicant: NATIONWIDE CHILDREN'S HOSPITAL INC.Inventors: Gail E. Besner, Osama N. El-Assal
-
Publication number: 20130142803Abstract: The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type IV pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and polypeptides encoded by the polynucleotides as well as polynucleotides and polypeptides encoded by the polynucleotides involved in the assembly/disassembly of the structure. The invention also relates to uses of these polynucleotides and/or polypeptides including methods for eliciting an immune response to H. influenzae and methods of treating and preventing H. influenzae related pathological conditions.Type: ApplicationFiled: February 13, 2013Publication date: June 6, 2013Applicant: Nationwide Children's Hospital, Inc.Inventor: Nationwide Children's Hospital, Inc.
-
Publication number: 20130130984Abstract: The invention provides for methods of protecting neurons within the enteric nervous system (ENS) comprising administering an EGF receptor agonist, such as heparin-binding EGF (HB-EGF). These methods include reducing damage of ENS neurons in patient s suffering from an intestinal injury. In addition, the invention provides for increasing intestinal motility in a patient suffering from an intestinal injury comprising administering HB-EGF. The invention also provides for methods of inducing neurite growth within the ENS in a patient suffering from intestinal injury comprising administering HB-EGF.Type: ApplicationFiled: November 6, 2012Publication date: May 23, 2013Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventor: Nationwide Children's Hospital, Inc.
-
Publication number: 20130105523Abstract: A fluid container spray device having a trigger lock mechanism with trigger tabs extending outwardly from the trigger and cleats extending inwardly from a moveable shroud. The cleats obstruct the tabs when the shroud is in a trigger lock position. A lever extending from beneath the shroud can be depressed, thereby moving the shroud from the trigger lock position to a trigger release position. The movement of the shroud to the trigger release position moves the connected cleats from their obstructive position to a position out of the trigger tabs' path of movement, thereby permitting use of the trigger to pump fluid from the container. The shroud is biased toward the trigger lock position. Thus, release of the container by the user restores the locked configuration, thereby preventing use by children.Type: ApplicationFiled: November 2, 2011Publication date: May 2, 2013Applicants: Nationwide Children's Hospital, Inc., The Ohio State UniversityInventors: Carolina Gill, Blaine Lilly, Thornton K. Lothrop, Scott Shim, Lara B. McKenzie, Kristin J. Roberts, Nicolas G. Nelson
-
Patent number: 8409842Abstract: The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, the invention relates to use of recombinant adenovirus encoding adeno-associated virus protein in recombinant adeno-associated virus production methods.Type: GrantFiled: March 18, 2009Date of Patent: April 2, 2013Assignee: Nationwide Children's Hospital, Inc.Inventors: Kelly Reed Clark, Philip R. Johnson, Jr.
-
Publication number: 20130078254Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.Type: ApplicationFiled: September 12, 2012Publication date: March 28, 2013Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Lauren O. Bakaletz, Robert S. Munson, JR., David W. Dyer
-
Patent number: 8399000Abstract: The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and polypeptides encoded by the polynucleotides as well as polynucleotides and polypeptides encoded by the polynucleotides involved in the assembly/disassembly of the structure. The invention also relates to uses of these polynucleotides and/or polypeptides including methods for eliciting an immune response to H. influenzae and methods of treating and preventing H. influenzae related pathological conditions.Type: GrantFiled: January 12, 2011Date of Patent: March 19, 2013Assignee: Nationwide Children's Hospital, Inc.Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr.
-
Publication number: 20130064828Abstract: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention.Type: ApplicationFiled: September 10, 2012Publication date: March 14, 2013Applicant: Nationwide Children's Hospital, Inc.Inventors: Lauren O. Bakaletz, Robert S. Munson, JR.
-
Publication number: 20130039888Abstract: The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering ?-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA.Type: ApplicationFiled: June 7, 2012Publication date: February 14, 2013Applicant: NATIONWIDE CHILDREN'S HOSPITAL INC.Inventors: Douglas M. McCarty, Haiyan Fu
-
Publication number: 20130017204Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.Type: ApplicationFiled: July 19, 2012Publication date: January 17, 2013Applicants: THE BOARD OF REGENTS OF UNIVERSITY OF OKLAHOMA, NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Lauren O. Bakaletz, Robert S. Munson, JR., David W. Dyer
-
Publication number: 20120329760Abstract: Methods of identifying a subject having a urinary tract infection using RNase 7 are described. The methods include providing a test sample of urine from the subject, determining the level of RNase 7 in the test sample, and then comparing the level of RNase 7 in the test sample to the level of RNase 7 in a control. A higher level of RNase 7 in the test sample indicates that the subject has an acute urinary tract infection, whereas a lower level of RNase 7 in the test sample indicates that the subject only has a chronic urinary tract infection.Type: ApplicationFiled: April 19, 2012Publication date: December 27, 2012Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: David Hains, Andrew Lawrence Schwaderer, John David Spenser
-
Publication number: 20120301402Abstract: A method for assessing if a subject has or is at risk of developing cardiac arrhythmia is described. The method includes determining the activity of Rap1A protein in a bodily sample of the subject and comparing the activity of Rap1A protein from the bodily sample of the subject to at least one Rap1A control. A decreased level of Rap1A activity in the bodily sample of the subject as compared to the at least one Rap1A control indicates that the subject is at risk of developing or has cardiac arrhythmia. Methods for evaluating the efficacy of treatment of a subject having decreased Rap1A activity with an antiarrhythmic agent are also described.Type: ApplicationFiled: April 27, 2012Publication date: November 29, 2012Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Maqsood Ahmed Chotani, John Anthony Bauer, Mandar Shankar Joshi, Selvi Chrysolyte Jeyaraj
-
Patent number: 8283114Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.Type: GrantFiled: June 15, 2006Date of Patent: October 9, 2012Assignees: Nationwide Children's Hospital, Inc., The Board of Regents of University of OklahomaInventors: Lauren O. Bakaletz, Robert S. Munson, Jr., David W. Dyer
-
Patent number: 8263363Abstract: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention.Type: GrantFiled: October 5, 2010Date of Patent: September 11, 2012Assignee: Nationwide Children's Hospital, Inc.Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr.
-
Patent number: D685268Type: GrantFiled: November 22, 2011Date of Patent: July 2, 2013Assignees: Nationwide Children's Hospital, Inc., The Ohio State UniversityInventors: Carolina Gill, Blaine Lilly, Thornton K. Lothrop, Scott Shim, Lara B. McKenzie, Kristin J. Roberts, Nicolas G. Nelson